BioNexus Gene Lab Corp (BGLC) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, BioNexus Gene Lab reported revenue of $7.4M, down 21.9% from $9.5M the year before. Net income was -$3.0M (a -40.2% net margin). Gross margin was 14.6% and operating margin was -39.9%. Operating activities generated -$1.8M of cash, leaving -$1.9M of free cash flow. At fiscal year end, BioNexus Gene Lab held $9.3M in total assets against $637,856 in total liabilities, including $2.5M of cash and equivalents.
Open the full interactive BioNexus Gene Lab financials → Quarterly statements, key ratios, valuation history and price charts.
BioNexus Gene Lab Key Stats
| Share Price | $1.32 |
|---|---|
| Market Cap | $3.2M |
| Revenue YoY Growth | -21.9% |
| 52-Week Range | $1.20 – $5.48 |
| Shares Outstanding | 17.1 million (basic, 2021 Q3) |
BioNexus Gene Lab Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.4M | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Gross Profit | $1.7M | $2.2M | $1.3M | $1.3M | $1.3M | $1.1M |
| Operating Income | $1.3M | $1.1M | -$291,177 | -$2.6M | -$1.6M | -$3.0M |
| Pre-Tax Income | $1.1M | $751,571 | -$303,656 | -$2.6M | -$1.6M | -$3.0M |
| Income Tax | — | — | -$52,310 | -$21,526 | -$3,494 | $0 |
| Net Income | $1.1M | $751,571 | -$355,966 | -$2.6M | -$1.6M | -$3.0M |
| Diluted EPS | $0.12 | — | — | — | -$0.09 | — |
BioNexus Gene Lab Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.5M | $483,760 | $22,842 | $76,156 |
| Net Income | -$708,991 | -$1.0M | -$543,575 | -$286,451 |
| Diluted EPS | -$0.40 | — | -$0.23 | -$0.12 |
BioNexus Gene Lab Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.8M | $2.1M | — | — | — | $2.5M |
| Current Assets | $8.0M | $7.1M | $6.0M | $8.0M | $7.4M | $5.4M |
| Total Assets | $10.1M | $9.6M | $8.7M | $11.4M | $10.4M | $9.3M |
| Current Liabilities | $3.4M | $2.3M | $2.0M | $1.6M | $2.0M | $520,957 |
| Total Liabilities | $3.5M | $2.4M | $2.1M | $1.7M | $2.1M | $637,856 |
| Shareholders' Equity | $6.7M | $7.2M | $6.7M | $9.7M | $8.3M | $8.6M |
BioNexus Gene Lab Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $552,680 | $9,161 | $544,028 | -$1.3M | -$2.2M | -$1.8M |
| Cash From Investing | $1.3M | -$490,574 | -$450,498 | -$382,576 | $418,202 | $944,751 |
| Cash From Financing | -$4,947 | -$28,222 | $115,962 | $5.8M | $144,975 | $298,841 |
| Free Cash Flow | $131,059 | $5,999 | $489,857 | -$1.3M | -$2.5M | -$1.9M |
Figures from BioNexus Gene Lab's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BioNexus Gene Lab financials page for every line item.
BioNexus Gene Lab Company Profile
| Ticker | BGLC |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Kuala Lumpur |
| Incorporated in | Wyoming |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001737523 |
Frequently Asked Questions
What was BioNexus Gene Lab's revenue in fiscal 2025?
BioNexus Gene Lab (BGLC) reported revenue of $7.4M for fiscal 2025.
What is BioNexus Gene Lab's annual revenue history?
BioNexus Gene Lab's annual revenue by fiscal year: 2020: $11.4M; 2021: $13.4M; 2022: $10.9M; 2023: $9.8M; 2024: $9.5M; 2025: $7.4M.
What was BioNexus Gene Lab's net income in fiscal 2025?
BioNexus Gene Lab reported net income of -$3.0M for fiscal 2025.
How much free cash flow did BioNexus Gene Lab generate in fiscal 2025?
BioNexus Gene Lab generated -$1.9M of free cash flow in fiscal 2025.
What was BioNexus Gene Lab's revenue last quarter?
In its most recent reported quarter (2026 Q2), BioNexus Gene Lab reported revenue of $76,156.
How many shares of BioNexus Gene Lab are outstanding?
BioNexus Gene Lab reported a weighted average of 17.1 million basic shares outstanding in 2021 Q3.
What is BioNexus Gene Lab's market cap?
Based on its latest closing price, BioNexus Gene Lab (BGLC) has a market capitalization of about $3.2M.
When does BioNexus Gene Lab's fiscal year end?
BioNexus Gene Lab's fiscal year end, as registered with the SEC, is December 31.
Where is BioNexus Gene Lab headquartered?
BioNexus Gene Lab lists its business address in Kuala Lumpur in its SEC filings.